IT1398781B1 - OLIGONUCLEOTIDES, PROCEDURE AND KITS FOR REAL TIME PCR REVELATION AND QUANTIFICATION OF GENE MN1 EXPRESSION AS A MINIMUM RESIDUAL DISEASE MARKER IN PATIENTS WITH ACUTE MIELOID LEUKEMIA (LAM) - Google Patents
OLIGONUCLEOTIDES, PROCEDURE AND KITS FOR REAL TIME PCR REVELATION AND QUANTIFICATION OF GENE MN1 EXPRESSION AS A MINIMUM RESIDUAL DISEASE MARKER IN PATIENTS WITH ACUTE MIELOID LEUKEMIA (LAM)Info
- Publication number
- IT1398781B1 IT1398781B1 ITTO2009A000685A ITTO20090685A IT1398781B1 IT 1398781 B1 IT1398781 B1 IT 1398781B1 IT TO2009A000685 A ITTO2009A000685 A IT TO2009A000685A IT TO20090685 A ITTO20090685 A IT TO20090685A IT 1398781 B1 IT1398781 B1 IT 1398781B1
- Authority
- IT
- Italy
- Prior art keywords
- mieloid
- revelation
- lam
- oligonucleotides
- leukemia
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
- 230000001154 acute effect Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000032839 leukemia Diseases 0.000 title 1
- 239000003550 marker Substances 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 238000011002 quantification Methods 0.000 title 1
- 238000003753 real-time PCR Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITTO2009A000685A IT1398781B1 (en) | 2009-09-07 | 2009-09-07 | OLIGONUCLEOTIDES, PROCEDURE AND KITS FOR REAL TIME PCR REVELATION AND QUANTIFICATION OF GENE MN1 EXPRESSION AS A MINIMUM RESIDUAL DISEASE MARKER IN PATIENTS WITH ACUTE MIELOID LEUKEMIA (LAM) |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITTO2009A000685A IT1398781B1 (en) | 2009-09-07 | 2009-09-07 | OLIGONUCLEOTIDES, PROCEDURE AND KITS FOR REAL TIME PCR REVELATION AND QUANTIFICATION OF GENE MN1 EXPRESSION AS A MINIMUM RESIDUAL DISEASE MARKER IN PATIENTS WITH ACUTE MIELOID LEUKEMIA (LAM) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ITTO20090685A1 ITTO20090685A1 (en) | 2011-03-08 |
| IT1398781B1 true IT1398781B1 (en) | 2013-03-18 |
Family
ID=41564189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ITTO2009A000685A IT1398781B1 (en) | 2009-09-07 | 2009-09-07 | OLIGONUCLEOTIDES, PROCEDURE AND KITS FOR REAL TIME PCR REVELATION AND QUANTIFICATION OF GENE MN1 EXPRESSION AS A MINIMUM RESIDUAL DISEASE MARKER IN PATIENTS WITH ACUTE MIELOID LEUKEMIA (LAM) |
Country Status (1)
| Country | Link |
|---|---|
| IT (1) | IT1398781B1 (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8206920B2 (en) * | 2007-03-26 | 2012-06-26 | Arnold Ganser | Diagnostic assay for the specific treatment of acute myeloid leukemia |
-
2009
- 2009-09-07 IT ITTO2009A000685A patent/IT1398781B1/en active
Also Published As
| Publication number | Publication date |
|---|---|
| ITTO20090685A1 (en) | 2011-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FIC20240036I1 (en) | Gene therapy expressing the R338L variant of human coagulation factor IX | |
| BRPI0922688A2 (en) | statistical validation of candidate genes | |
| DK2417257T3 (en) | TRICYCLO DNA ANTISENSE OLIGONUCLEOTIDES, COMPOSITIONS, AND PROCEDURES FOR THE TREATMENT OF DISEASE | |
| EP2255809A4 (en) | MEDICAMENT STAMP | |
| IL246697A0 (en) | A multiple axon ablation preparation for the treatment of muscular dystrophy | |
| PT2367561E (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CELIAC DISEASE | |
| HUE036780T2 (en) | New compositions and methods for treating immunologically related diseases | |
| BRPI0817437A2 (en) | Surgical Implant with an Antiretrocess Feature | |
| BR112012006644A2 (en) | compound, method of treating a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder or a neuronal disorder, pharmaceutical composition, use of a compound and kit | |
| BRPI0913988A2 (en) | set and process for providing an implant stent | |
| BR112012006648A2 (en) | compound, method of treating a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder or a neuronal disorder, pharmaceutical composition and kit | |
| BR112012006640A2 (en) | compound, pharmaceutical composition, method of treating a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder or a neuronal disorder, and kit | |
| DK2379018T3 (en) | prosthetic Coatings | |
| IL207641A0 (en) | Compositions comprising nucleic acids encoding vegf antagonists for use in treating ocular disease | |
| HUE038785T2 (en) | Traditional Chinese medicine for the treatment of cardiovascular diseases | |
| BRPI0909416A2 (en) | Medical devices with hydrophilic coatings | |
| DE602007013699D1 (en) | COATING COMPOSITIONS WITH IMPROVED EARLY HARDNESS | |
| BRPI0811623A2 (en) | METHODS FOR IDENTIFYING GENES INVOLVED IN MEMORY FORMATION USING SMALL INTERFERENT RNA (SIRNA) | |
| JP2009215191A5 (en) | ||
| SMT201600156B (en) | TREATMENT OF OSTEOARTRITIS | |
| BRPI0921454A2 (en) | methods for treating a cancer patient, and for identifying cancer stem cells | |
| ITBO20080103A1 (en) | MICROARRAY FOR ANALYSIS OF NUCLEOTID SEQUENCES | |
| BRPI1013184A2 (en) | method of identifying a compound usable in the treatment of an oral cavity disease or condition | |
| PL2320878T3 (en) | Monoterpenes for the treatment of respiratory diseases, in particular bronchopulmonary diseases | |
| EP1970078A4 (en) | COMPOSITION FOR INHIBITING A TARGET GENE IN AN EYEBORN AND REMEDY FOR ACAPIC DISEASE |